BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
82.98
+3.09 (3.87%)
At close: Aug 18, 2026, 4:00 PM EDT
83.20
+0.22 (0.27%)
After-hours: Aug 18, 2026, 7:54 PM EDT
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $243.68M in the quarter ending June 30, 2026, with 120.39% growth. This brings the company's revenue in the last twelve months to $713.07M, up 202.39% year-over-year. In the year 2025, BridgeBio Pharma had annual revenue of $502.08M with 126.26% growth.
Revenue (ttm)
$713.07M
Revenue Growth
+202.39%
P/S Ratio
22.75
Revenue / Employee
$710,936
Employees
1,003
Market Cap
16.22B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 502.08M | 280.17M | 126.26% |
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| BioMarin Pharmaceutical | 3.41B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Ascendis Pharma | 1.20B |
BBIO News
- 2 days ago - BridgeBio Oncology announces 5M common stock offering for holders - TheFly
- 4 days ago - BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base - GlobeNewsWire
- 5 days ago - BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder - GlobeNewsWire
- 7 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - BridgeBio price target raised to $110 from $95 at TD Cowen - TheFly
- 7 days ago - BridgeBio price target lowered to $97 from $98 at Morgan Stanley - TheFly
- 7 days ago - BridgeBio price target raised to $102 from $98 at Wells Fargo - TheFly
- 7 days ago - BridgeBio price target raised to $115 from $111 at Piper Sandler - TheFly